Browsing by Subject "I-TRANSFORMED-CELLS"

Now showing items 1-10 of 10

Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocyte leukemia and adult T-cell leukemia-lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity

Dbaibo G.S.; Kfoury Y.; Darwiche N.; Panjarian S.; Kozhaya L.; Nasr R.; Abdallah M.; Hermine O.; El-Sabban M.; De The H.; Bazarbachi A. (PAVIASTRADA NUOVA 134, 27100 PAVIA, ITALY, 2007)

Background and Objectives: Arsenic trioxide (ATO) is an effective treatment for acute promyelocytic leukemia (APL) and potentially for human T-cell leukemia virus type I (HTLV-I) associated adult T-cell leukemia-lymphoma ...
Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas

El Hajj H.; Ali J.; Ghantous A.; Hodroj D.; Daher A.; Zibara K.; Journo C.; Otrock Z.; Zaatari G.; Mahieux R.; El Sabban M.; Bazarbachi A.; Merhi R.A. (SAN FRANCISCO1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA, 2013)

Background: Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in ...
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha

El Eit R.M.; Iskandarani A.N.; Saliba J.L.; Jabbour M.N.; Mahfouz R.A.; Bitar N.M.A.; El Ayoubi H.R.; Zaatari G.S.; Mahon F.-X.; De The H.B.; Bazarbachi A.A.; Nasr R.R. (HOBOKEN111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2014)

Imatinib is the standard of care in chronic meloid leukemia (CML) therapy. However, imatinib is not curative since most patients who discontinue therapy relapse indicating that leukemia initiating cells (LIC) are resistant. ...
How animal models of leukaemias have already benefited patients

Ablain J.; Nasr R.; Zhu J.; Bazarbachi A.; Lallemand-Breittenbach V.; De The H. (OXFORDTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, 2013)

The relative genetic simplicity of leukaemias, the development of which likely relies on a limited number of initiating events has made them ideal for disease modelling, particularly in the mouse. Animal models provide ...
Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia-lymphoma

El Hajj H.; Khalil B.; Ghandour B.; Nasr R.; Shahine S.; Ghantous A.; Abdel-Samad R.; Sinjab A.; Hasegawa H.; Jabbour M.; Hall W.W.; Zaatari G.; Dbaibo G.; Pisano C.; Bazarbachi A.; Darwiche N. (American Society of Hematology; WASHINGTON2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, 2014)

Adult T-cell leukemia-lymphoma (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1). The HTLV-1 oncoprotein Tax plays an important role in ATL pathogenesis. ATL carries a poor prognosis due ...
PS-341 or a combination of arsenic trioxide and interferon-α inhibit growth and induce caspase-dependent apoptosis in KSHV- HHV-8-infected primary effusion lymphoma cells

Abou-Merhi R.; Khoriaty R.; Arnoult D.; El Hajj H.; Dbouk H.; Munier S.; El-Sabban M.E.; Hermine O.; Gessain A.; de The H.; Mahieux R.; Bazarbachi A. (LONDONMACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, 2007)

Kaposi's sarcoma (KS)-associated herpes virus (KSHV) is the causative agent of primary effusion lymphoma and of KS. Primary effusion lymphoma (PEL) is an aggressive proliferation of B cells. Conventional chemotherapy has ...
The combination of arsenic, interferon-alpha, and zidovudine restores an immunocompetent-like cytokine expression profile in patients with adult T-cell leukemia lymphoma

Kchour G.; Rezaee S.A.R.; Farid R.; Ghantous A.; Rafatpanah H.; Tarhini M.; Kooshyar M.-M.; El Hajj H.; Berry F.; Mortada M.; Nasser R.; Shirdel A.; Dassouki Z.; Ezzedine M.; Rahimi H.; Ghavamzadeh A.; de The H.; Hermine O.; Mahmoudi M.; Bazarbachi A. (LONDON236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND, 2013)

Background: HTLV-I associated adult T-cell leukemia-lymphoma (ATL) carries a dismal prognosis due to chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and interferon-alpha (IFN) ...
The drug-induced degradation of oncoproteins: An unexpected achilles' heel of cancer cells?

Ablain J.; Nasr R.; Bazarbachi A.; de The H. (PHILADELPHIA615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA, 2011)

Many targeted therapies against cancer are aimed at inhibiting the enzymatic activity of kinases. Thus far, this approach has undoubtedly yielded significant clinical improvements, but has only rarely achieved cures. Other ...
The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus)

Heraud J.M.; Mortreux F.; Merien F.; Contamin H.; Mahieux R.; Pouliquen J.F.; Wattel E.; Gessain A.; de The H.; Bazarbachi A.; Hermine O.; Kazanji M. (AMSTERDAMPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS, 2006)

Human T-cell lymphotropic virus type 1 (HTLV-1)-associated adult T-cell leukemia-lymphoma (ATLL) has a poor prognosis owing to its intrinsic resistance to chemotherapy. Although zidovudine (AZT) and alpha interferon (IFN-α) ...
Therapeutic options for adult T-cell leukemia-lymphoma

Marcais A.; Suarez F.; Sibon D.; Frenzel L.; Hermine O.; Bazarbachi A. (NEW YORK233 SPRING ST, NEW YORK, NY 10013 USA, 2013)

Adult T-cell leukemia-lymphoma (ATL) is the first human malignancy associated with a retroviral infection and occurs in approximately 5 percent of the 15 million to 20 million people infected by human T-cell lymphotropic ...

Now showing items 1-10 of 10

Search AUB ScholarWorks

Browse

All of AUB ScholarWorks

My Account

Copyright Statement

All materials included in the institutional repository are protected by copyright laws and are the property of their respective copyright holders. Materials may be used for non-commercial, educational, or research purposes only, and must be cited or attributed to the original source. Permission for any other use must be obtained from the copyright holder(s) directly. The American University of Beirut Libraries does not assume responsibility for any infringement of copyright laws that may occur as a result of the use of materials in the repository. If you believe that your copyright has been infringed upon in the repository, please contact the AUB Libraries immediately.

For further information, please contact us at scholarworks@aub.edu.lb

Browsing by Subject "I-TRANSFORMED-CELLS"

Browsing by Subject "I-TRANSFORMED-CELLS"

Search AUB ScholarWorks

Browse

All of AUB ScholarWorks

My Account

Copyright Statement